^
    Back
    Association details:
    Biomarker:CLDN18.2 expression
    Cancer:Pancreatic Cancer
    Drug:AZD5863 (CD3 agonist, CLDN18.2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

    Excerpt:
    ...- Must show positive CLDN18.2 expression in tumor cells as determined by central immunohistochemistry (IHC)...
    Trial ID:
    NCT06005493
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    SITC 2023
    Title:

    1169 AZD5863: a specific, potent, affinity-optimized claudin 18.2 and CD3 binding T cell-engager that elicits low cytokine release and is capable of bystander killing

    Published date:
    11/04/2023
    Excerpt:
    In humanized mouse models, AZD5863 significantly inhibited the growth of CLDN18.2-expressing gastric, pancreatic and esophageal tumors compared with isotype controls.
    DOI:
    http://dx.doi.org/10.1136/jitc-2023-SITC2023.1169